The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pegylated liposomal doxorubicin (SCH 200746)|DRUG: Capecitabine
Sponsor: Merck Sharp & Dohme LLC
Collaborators: Essex Pharma GmbH